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ABSTRACT 
Background. Occupational exposure to acrylamide was associated with excess 
mortality from pancreatic cancer, though in the absence of dose-risk relationship. Few 
epidemiological studies have examined the association between acrylamide from diet 
and pancreatic cancer risk.  
Patients and methods. We considered this issue in a combined set of 1975 cases of 
pancreatic cancer and 4239 controls enrolled in six studies of the Pancreatic Cancer 
Case-Control Consortium (PanC4). We calculated pooled odds ratios (ORs) and their 
95% confidence intervals (CI) by estimating study-specific ORs through multivariate 
unconditional logistic regression models and pooling the obtained estimates using 
random-effects models.  
Results. Compared with the lowest level of estimated dietary acrylamide intake, the 
pooled ORs were 0.97 (95% CI, 0.79-1.19) for the second, 0.91 (95% CI, 0.71-1.16) for 
the third, and 0.92 (95% CI, 0.66-1.28) for the fourth (highest) quartile of intake. For an 
increase of 10 µg/day of acrylamide intake, the pooled OR was 0.96 (95% CI, 0.87-
1.06), with heterogeneity between estimates (I
2
 = 67%). Results were similar across 
various subgroups, and were confirmed when using a one-stage modelling approach.  
Conclusions. This PanC4 pooled-analysis found no association between dietary 
acrylamide and pancreatic cancer. 
 
Key words: acrylamide; case-control studies; pancreatic neoplasms; pooled-analysis; 
risk factors. 
 at Ist.Ricerche Farm
acol. on January 11, 2017
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
4 
 
Key message: In a combined set of 1975 cases of pancreatic cancer and 4239 controls 
enrolled in six studies of the Pancreatic Cancer Case-Control Consortium (PanC4), 
there was no association between dietary acrylamide and pancreatic cancer.  
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INTRODUCTION 
The association between dietary acrylamide intake and risk of several common cancers 
has been widely debated [1-5], following the findings of a Swedish study reporting the 
formation of acrylamide in foods, particularly starchy foods such as potatoes and 
breads, cooked at high temperatures [6].  
Epidemiological data on the association between dietary acrylamide and pancreatic 
cancer are scant. It is of particular interest to investigate this association because two 
studies of acrylamide exposure in the occupational setting [7, 8] have shown moderately 
increased mortality from pancreatic cancer, but with no evidence of a dose-risk 
relationship. When the results of those studies were pooled, the summary standardized 
mortality ratios (SMR) of pancreatic cancer were 1.54 (95% confidence interval, CI, 
0.95-2.36) for any occupational exposure to acrylamide and 1.67 (95% CI, 0.83-2.99) 
for high exposure [4]. In contrast, a recent systematic review and meta-analysis of 
epidemiological data considering exposure to dietary acrylamide reported relative risks 
(RR) of pancreatic cancer of 0.93 (95% CI, 0.76-1.12) for high vs. low acrylamide 
intake and of 0.99 (95% CI, 0.95-1.03) for an increase in intake equal to 10 µg/day. The 
estimates were based on 4 studies (3 cohort and 1 case-control study), with a total of 
1732 cases [5]. 
With the aim to provide additional evidence on this topic, given the scant amount of 
available epidemiological data, we examined the role of acrylamide intake on a 
combined set of 1975 cases of pancreatic cancer (i.e., more than those included in the 
meta-analysis) and over 4000 controls enrolled in six studies from the Pancreatic 
Cancer Case-Control Consortium (PanC4) [9].  
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MATERIALS AND METHODS 
PanC4 is an International consortium of scientists set up to investigate the aetiology of 
pancreatic cancer, through pooled analyses of shared data (http://www.panc4.org). This 
investigation is based on six case-control studies [10-15] with comprehensive food 
frequency questionnaires, including information on the major food items contributing 
acrylamide intake (e.g., potato products cooked at high temperatures, breads, coffee) as 
well as calculation of total energy intake. They included a total of 1975 cases and 4239 
controls. The main characteristics of the studies are described in Supplementary Table 
S1. A number of participants in three case-control studies included [11, 12, 14] lacked 
more than 10% of the required information to estimate acrylamide intake (i.e., they had 
not completed the food frequency questionnaires), and were therefore excluded from the 
analyses. Another PanC4 participating study from Shanghai, China [16], could not be 
included in the investigation since data on content of dietary acrylamide in Chinese 
foods was not available at the time of data analysis. Cases and controls were 
interviewed in-person in all studies except the Queensland (Australia) study, where 
interviews were conducted either over the telephone or face-to-face, with a self-
administered food frequency questionnaire.  
For the present analyses, the original datasets were restructured either by the original 
study investigators or by our central coordinators using a uniform format for data 
harmonization. From each study, individual data on socio-demographic characteristics, 
anthropometric measures, tobacco smoking and history of diabetes were collected, 
whenever available. 
 at Ist.Ricerche Farm
acol. on January 11, 2017
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
7 
 
The list of foods containing dietary acrylamide was derived from international databases 
[17-19], and included coffee, breads, potato products, various breakfast cereals, biscuits 
and cookies, gingerbread and spiced cakes, chocolate products (such as brownies and 
candy bars), several types of snacks and pastries, fried fish, fried chicken, pizza, tacos, 
fried rice and beer. Each participating study was asked to provide information on 
individual consumption of all these food items of cases and controls, whenever 
available in food frequency questionnaires, together with their cooking method 
whenever relevant (particularly for potato products). The total number of food items 
containing acrylamide in each study ranged from 14 (in the Louisiana State University 
study) to 33 (in the University of Minnesota study). Subjects who had a maximum of 
10% of missing information among the food items contributing to total acrylamide were 
maintained in the analyses, by assigning the missing food item information the study-
specific median frequency of consumption of that item. Information on total energy 
intake was also collected, for adjustment purposes. Data on the average acrylamide 
content of foods were derived from area-specific resources. Thus, for studies from the 
United States, we applied measures of acrylamide levels made available from the 
United States Food and Drug Administration (Total Diet Study 2003-2006 [18]); for the 
Italian study, we used data from the European Food Safety Agency [17] and the Agence 
Française de Sécurité Sanitaire des Aliments (AFSSA) [20], integrated with estimates 
on specific Italian dietary items [21, 22]; and for the Australian study, we used data 
from two complementary reports from the Government of South Australia (on non-
carbohydrate based foods [23]) and from Croft et al (on carbohydrate based foods [24]).  
 
 
 at Ist.Ricerche Farm
acol. on January 11, 2017
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
8 
 
Statistical analysis.  
A two-stage modelling approach was used to estimate the association between dietary 
acrylamide intake and risk of pancreatic cancer. In the first stage, we considered the 
association between acrylamide intake and risk of pancreatic cancer separately for each 
study, by estimating the odds ratios (ORs) and their 95% CI through multivariate 
unconditional logistic regression models [25], including a priori defined terms, when 
available, for age, sex, race/ethnicity, education, smoking habits, diabetes, body mass 
index, and total energy intake. The Italian study was further adjusted for two study-
specific covariates, i.e., period of interview and study centre. We modelled exposure 
using both study-specific quartiles and a continuous measure (i.e., 10 µg/day) of 
acrylamide intake. In the second stage, summary (pooled) effect estimates were 
computed using a random-effects model [26]. 
Heterogeneity between studies was examined using the χ
2
 statistic [27] and quantified 
through the I
2 
[28].  
Subgroup analyses were conducted to examine whether the effect of high vs. low 
acrylamide intake was heterogeneous across strata (through the χ
2
 statistic [27]) of sex, 
age, smoking habit, obesity, diabetes and geographic area of the study.  
In addition to the two-stage analysis, we performed an aggregate analysis by pooling 
data from all six studies into a single large dataset (one-stage analysis). The association 
between acrylamide intake and the risk of pancreatic cancer was then assessed through 
multivariate unconditional logistic regression models [25], adjusted for study and the 
same covariates reported above for the two-stage modelling approach. This analysis was 
conducted by including in the model the study-specific quartiles of acrylamide intake 
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or, in an additional sensitivity analysis, quartiles of acrylamide intake based on the 
distribution of all 4239 controls. We also conducted a sensitivity analysis in which each 
study was excluded one at a time to ensure that the magnitude of the overall estimates 
was not dependent on any specific study, and another one by excluding all subjects that 
had any missing information in food items contributing to total acrylamide intake (i.e., 
about 10% of cases and 8% of controls). 
 
RESULTS 
Supplementary Table S2 presents the distribution of pancreatic cancer cases and 
controls according to sex, age and other selected covariates.   
Table 1 gives information on estimates of dietary acrylamide intake in the six studies. 
The mean daily intake of acrylamide in cases ranged between 20.3 µg in the Louisiana 
State University study and 33.6 µg in the Italian study, and in controls between 16.8 µg 
and 31.2 µg (in the same studies). The median acrylamide intake of controls varied from 
a lowest value of 14.7 µg/day in the Louisiana State University study to a highest of 
28.2 µg/day in the Italian study. The main food categories contributing to total 
acrylamide intake in each study, and the corresponding contribution proportions, are 
reported in Supplementary Table S3. 
Figure 1 shows a forest plot, displaying the ORs and 95% CIs for each study and the 
pooled estimate, according to study-specific quartiles of acrylamide intake. Compared 
to the lowest study-specific quartile of dietary acrylamide intake, the pooled ORs were 
0.97 (95% CI, 0.79-1.19) for the second, 0.91 (95% CI, 0.71-1.16) for the third and 0.92 
(95% CI, 0.66-1.28) for the fourth (highest) quartile of intake. Heterogeneity of the risk 
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estimates between participating studies was low for the second (I
2
 = 24%), low to 
moderate for the third (I
2
 = 39%) and moderate to high for the fourth quartile of intake 
(I
2
 = 59%) [31]. Four sensitivity analyses were conducted. In the first, we pooled all 
studies into a single dataset and conducted an aggregate (one-stage) analysis. This gave 
an OR of 0.96 (95% CI, 0.80-1.16) for the highest vs. lowest study-specific quartile of 
intake. The second used the pooled dataset and calculated quartiles of intake based on 
the distribution in all controls, rather than being study-specific. This analysis found an 
OR of 0.98 (95% CI, 0.81-1.19) for the highest vs. the lowest quartile. In the third, we 
excluded one study at a time, and found ORs ranging from 0.84 (95% CI, 0.60-1.17, 
when excluding the Italian study) to 1.07 (95% CI, 0.86-1.33, when excluding the MD 
Anderson study) for the highest vs. lowest quartile of intake. In the fourth one, we 
excluded all subjects that had any missing information in food items contributing to 
total acrylamide: the pooled OR for high vs. low acrylamide intake, based on 1766 
cases and 3885 controls, was 0.96 (95% CI, 0.74-1.26). 
Figure 2 shows the ORs and 95% CIs for each study and the pooled estimate for an 
increase of 10 µg/day of dietary acrylamide intake. The latter was 0.96 (95% CI, 0.87-
1.06), with high heterogeneity between estimates (I
2
 = 67%). When studies were pooled 
into a single dataset (one-stage analysis), the OR per 10 µg/day of dietary acrylamide 
intake was 0.98 (95% CI, 0.93-1.02). 
Table 2 presents the results of analyses of high compared to low dietary acrylamide 
intake, stratified by sex, age, smoking habit, BMI and study area. None of the summary 
estimates in any subgroup examined was significantly different from unity. No 
significant differences were observed between subgroups (all p-values were >0.05). 
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DISCUSSION 
This large individual-level pooled-analysis from the PanC4 study reported no evidence 
of increased pancreatic cancer risk associated with estimated intake of acrylamide. All 
pooled risk estimates for increasing acrylamide intake were below unity, and none of 
the studies included showed significant positive associations between dietary 
acrylamide and pancreatic cancer. These findings were not substantively changed by a 
number of sensitivity analyses, and were consistent in strata of smoking habit and other 
individual-level and study-level covariates.  
Only three cohort studies [29-31] and one case-control study (included in this 
investigation, too [32]) have previously reported results on acrylamide from diet in 
relation to the risk of pancreatic cancer. None showed increases in risk in participants 
with high compared to low acrylamide intake. The largest analysis, from the European 
Prospective Investigation into Cancer and Nutrition (EPIC) study, was based on 865 
cases and reported ORs of 0.77 (95% CI, 0.58-1.04) for high vs. low acrylamide and 
0.95 (95% CI, 0.89-1.01) for each 10 µg/day increase in intake [29]. Overall, our results 
are consistent with those from a meta-analysis of the four previous studies [5], thus 
confirming in a larger dataset – and with the advantages of an individual data approach 
– the lack of an association between acrylamide intake and pancreatic cancer risk. With 
further reference to potential associations in specific population subgroups, an inverse 
relation emerged among obese subjects in the EPIC analysis [29]. This was not, 
however, confirmed in our dataset.  
We computed the estimates of acrylamide intake using food frequency questionnaires 
combined with databases of mean content of acrylamide in foods. Still, the amount of 
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acrylamide varies widely within different samples of the same food item, due to 
variations in cooking procedures (e.g., duration of cooking, temperature, etc.), food 
characteristics (e.g., potato variety) and storage, or product brand (e.g., for breakfast 
cereals, chips, etc.). Further, we estimated intakes in populations from different 
continents, enrolled during different time periods, and acrylamide food contents vary 
across geographic areas (e.g., higher values for white bread in Europe than in USA) and 
over the years. We tried to overcome these problems by using area-specific databases of 
acrylamide content in foods. As a consequence, a Chinese study of the PanC4 [16] was 
not included in this investigation since area-specific information on acrylamide content 
in food was not available at the time of analysis. With reference to variations in 
acrylamide food contents over the years, manufacturers’ measurements reported a 
substantial downward trend since 2002, more for potato crisps/chips than for other 
foods [33]. None of the acrylamide-rich foods, and notably coffee, has in any case been 
associated with pancreatic cancer risk [34]. Early symptoms of disease might also have 
led to diet modifications in pancreatic cancer cases. Epidemiological studies using 
biomarkers of acrylamide exposure would be needed to overcome most of these 
limitations. Strengths of this study are its large size and the consortium, individual-
level, data approach, with consequent availability of detailed and harmonized 
information for relevant covariates. Also, we performed various sensitivity analyses to 
assess the robustness of results, and no meaningful differences emerged.        
Acrylamide may play a role in the aetiology of cancer through its oxidization to 
glycidamide, a chemically reactive genotoxic metabolite [35], and – for selected body 
sites, such as endometrial and ovarian cancer – by affecting hormonal balances in 
humans [36]. To date, however, epidemiological studies found no evidence of any 
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relationship for cancers of the digestive organs [5]. Findings from this PanC4 pooled-
analysis further support a lack of association between dietary acrylamide and pancreatic 
cancer.   
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FIGURE TITLES 
 
Figure 1. Study-specific and pooled odds ratios (OR), and corresponding 95% 
confidence intervals (CI), of pancreatic cancer according to quartiles of acrylamide 
intake, with the lowest intake being the reference. International Pancreatic Cancer Case-
Control Consortium (PanC4). 
 
Figure 2. Study-specific and pooled odds ratios (OR), and corresponding 95% 
confidence intervals (CI), of pancreatic cancer according to an increase of 10 µg/day in 
acrylamide intake. International Pancreatic Cancer Case-Control Consortium (PanC4). 
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Table 1. Information on daily acrylamide intake in the studies considered in the analyses. International Pancreatic Cancer Case-Control Consortium 
(PanC4). 
Study centre Mean intake 
± SD, cases 
(µg/day)
 
Mean intake ± 
SD, controls 
(µg/day) 
25
th
 
percentile 
(µg/day)
1 
Median 
intake 
(µg/day)
1
 
75
th
 
percentile 
(µg/day)
1 
Mean intake ± SD 
per kg of BW, cases 
(µg/day/kg BW)
 
Mean intake ± SD per 
kg of BW, controls 
(µg/day/kg BW) 
MD Anderson, USA 20.5 ± 12.5 22.2 ± 13.7 12.5 19.0 28.0 0.25 ± 0.16 0.27 ± 0.17 
Italy 33.6 ± 15.9 31.2 ± 17.2 19.1 28.2 39.6 0.47 ± 0.24 0.43 ± 0.24 
UCSF, USA 22.7 ± 13.7 20.7 ± 14.5 11.9 17.6 26.0 0.31 ± 0.18 0.29 ± 0.20 
LSU, USA 20.3 ± 14.8 16.8 ± 11.2 8.3 14.7 22.2 0.25 ± 0.18 0.22 ± 0.16 
UMN, USA 25.3 ± 14.4 26.0 ± 14.6 16.5 23.1 31.9 NA 
2
 NA 
2
 
QIMR, Australia
 22.8 ± 16.6 20.0 ± 11.1 12.5 17.8 25.5 0.29 ± 0.22 0.26 ± 0.16 
1
 Among controls. 
2
 Information on body weight was not available in the University of Minnesota study. 
BW, body weight; LSU, Louisiana State University; NA, not available; QIMR, QIMR Berghofer Medical Research Institute; SD, standard 
deviation; UCSF, University of California, San Francisco; UMN, University of Minnesota. 
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Table 2. Pooled odds ratios (OR), and corresponding 95% confidence intervals (CI), of pancreatic cancer for high versus low acrylamide intake, 
overall and in strata of selected covariates. International Pancreatic Cancer Case-Control Consortium (PanC4). 
 Low intake (1
st
 quartile) High intake (4
th
 quartile)   
Covariate Cases, n (%) Controls, n (%) Cases, n (%) Controls, n (%) OR (95% CI) 
a 
p-value 
b 
Overall 450 (22.8) 1057 (24.9) 559 (28.3) 1064 (25.1) 0.92 (0.66-1.28) - 
       
Sex       
Male 207 (18.0) 471 (20.2) 375 (32.6) 695 (29.8) 0.78 (0.44-1.36)  
Female 243 (29.4) 586 (30.7) 184 (22.3) 369 (19.3) 1.16 (0.67-2.01) 0.32 
       
Age       
<65 181 (19.0) 469 (23.1) 299 (31.3) 549 (27.1) 0.88 (0.51-1.51)  
≥65 269 (26.3) 588 (26.6) 260 (25.5) 515 (23.3) 0.94 (0.72-1.23) 0.83 
       
Smoking habit       
Never smokers 204 (27.7) 528 (27.8) 179 (24.3) 416 (21.9) 1.08 (0.79-1.47)  
Former cigarette smokers 167 (22.4) 414 (24.0) 220 (29.4) 459 (26.6) 0.79 (0.50-1.23)  
Current cigarette smokers 72 (16.2) 95 (18.8) 144 (32.5) 164 (32.5) 0.56 (0.22-1.46) 0.29 
       
Body mass index (BMI) 
c       
<30 kg/m
2
 315 (22.3) 768 (24.8) 402 (28.4) 779 (25.2) 0.93 (0.60-1.43)  
≥30 kg/m
2
 75 (20.9) 142 (24.7) 107 (29.8) 143 (24.9) 0.90 (0.46-1.78) 0.94 
       
Diabetes       
No 347 (22.2) 957 (25.0) 442 (28.3) 953 (24.9) 0.92 (0.65-1.30)  
Yes 
d 
96 (24.5) 100 (24.4) 111 (28.3) 111 (27.1) 0.79 (0.41-1.51) 0.69 
       
Study area       
USA (4 studies) 305 (24.2) 744 (24.9) 336 (26.6) 750 (25.1) 0.80 (0.50-1.26)  
Other (2 studies) 145 (20.3) 313 (25.0) 223 (31.2) 314 (25.1) 1.17 (0.77-1.77) 0.23 
a 
 ORs from multivariate logistic regression models adjusted for age, sex, race/ethnicity, education, smoking habits, diabetes, body mass index, and 
total energy intake. 
b
 p-value for heterogeneity between strata. 
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c
 Information was not available in the University of Minnesota study, thus the OR estimates on acrylamide intake in strata of BMI are based on 5 
studies. 
d
 OR estimate is based on 5 studies, since for the LSU study there were too few diabetic patients for the model to converge. 
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